M. Yu. En
Research Subjects
M. Yu. En has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Tamila V. Martynyuk
E.I. Chazov National Medical Research Center of Cardiology; N.I. Pirogov Russian National Research Medical University
3 shared publications - Archil M. Shariya
E.I. Chazov National Medical Research Center Of Cardiology
2 shared publications - Zarina S. Valieva
Chazov National Medical Research Center of Cardiology
2 shared publications - E. A. Nikolaeva
A.L. Myasnikov Scientific research institute of clinical cardiology, E.I. Chazov National Medical Research Center of cardiology
1 shared publication - E. A. Rezukhina
E.I. Chazov National Medical Research Center Of Cardiology
1 shared publication - Tatiana N. Veselova
E.I. Chazov National Medical Research Center Of Cardiology
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 23 (3) , 31-38
Analysis of pulmonary perfusion in patients with idiopathic pulmonary hypertension on therapy using lung subtraction CT
Relevance . It is known that patients with idiopathic pulmonary hypertension (IPH) develop characteristic patchy defects of lung tissue perfusion. According to the literature, patients with severe perfusion disorders tended to have a more severe course of the disease than patients with relatively normal lung tissue perfusion and were more often treated with pathogenetic therapy. Thus, the study of lung perfusion in patients with IPH on the background of specific therapy is of particular scientific and practical interest. Objective . To evaluate lung perfusion in patients with IPH depending on clinical, functional, and hemodynamic parameters during specific therapy using subtraction computed tomography pulmonary angiography. Materials and methods . Twenty patients with a newly diagnosed IPH, according to clinical guidelines, were enrolled in the study at the Tomography Department of the A.L. Myasnikov Institute of Cardiology and Cardiology, E.I. Chazov National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation. All patients underwent subtraction CT pulmonary angiography using an Aquilion ONE 640 VISION Edition CT scanner with 320 detector rows, using the lung subtraction protocol. Analysis of the obtained images included a visual segmental assessment of perfusion using iodine maps during the initial and repeat CT scans (after at least 6 months of stable PAH therapy). Results . A significant correlation was found between the baseline perfusion index (PI) 32.5 [19.4; 43.7]% and the initial mean pulmonary artery pressure (before specific therapy) according to right heart catheterization 61.5 [54.5; 68.7] mmHg (r=0,6, p =0,007), and transthoracic echocardiography 62.5 [53.7; 73.7] mmHg (r=0,8, p=0,001). When assessing the dynamics against the background of therapy, an improvement in lung perfusion was noted. The initial values of IP were 32.5% [19.4; 43.7], after the prescription of therapy 22.5% [14.4; 30], p=0,038. Conclusion . Subtraction CT angiopulmonography with assessment of lung perfusion can potentially be used as an additional method in assessing the severity of patients with IPH. Also, the study of the perfusion of the lung tissue in dynamics may be of interest in order to assess the results of the ongoing treatment.
- 29 October 2026
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 23 (3) , 31-38
Open AccessAnalysis of pulmonary perfusion in patients with idiopathic pulmonary hypertension on therapy using lung subtraction CT
Relevance . It is known that patients with idiopathic pulmonary hypertension (IPH) develop characteristic patchy defects of lung tissue perfusion. According to the literature, patients with severe perfusion disorders tended to have a more severe course of the disease than patients with relatively normal lung tissue perfusion and were more often treated with pathogenetic therapy. Thus, the study of lung perfusion in patients with IPH on the background of specific therapy is of particular scientific and practical interest. Objective . To evaluate lung perfusion in patients with IPH depending on clinical, functional, and hemodynamic parameters during specific therapy using subtraction computed tomography pulmonary angiography. Materials and methods . Twenty patients with a newly diagnosed IPH, according to clinical guidelines, were enrolled in the study at the Tomography Department of the A.L. Myasnikov Institute of Cardiology and Cardiology, E.I. Chazov National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation. All patients underwent subtraction CT pulmonary angiography using an Aquilion ONE 640 VISION Edition CT scanner with 320 detector rows, using the lung subtraction protocol. Analysis of the obtained images included a visual segmental assessment of perfusion using iodine maps during the initial and repeat CT scans (after at least 6 months of stable PAH therapy). Results . A significant correlation was found between the baseline perfusion index (PI) 32.5 [19.4; 43.7]% and the initial mean pulmonary artery pressure (before specific therapy) according to right heart catheterization 61.5 [54.5; 68.7] mmHg (r=0,6, p =0,007), and transthoracic echocardiography 62.5 [53.7; 73.7] mmHg (r=0,8, p=0,001). When assessing the dynamics against the background of therapy, an improvement in lung perfusion was noted. The initial values of IP were 32.5% [19.4; 43.7], after the prescription of therapy 22.5% [14.4; 30], p=0,038. Conclusion . Subtraction CT angiopulmonography with assessment of lung perfusion can potentially be used as an additional method in assessing the severity of patients with IPH. Also, the study of the perfusion of the lung tissue in dynamics may be of interest in order to assess the results of the ongoing treatment.
- Open Access
- 24 February 2026
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 46-53
Analysis of quality of life indicators using various questionnaires in patients with idiopathic pulmonary hypertension.
Idiopathic pulmonary hypertension (IPAH) is a rare severe disease with a poor prognosis. Assessing quality of life (QoL) using questionnaires can significantly complement clinical, laboratory and instrumental data. Aim . To assess QoL using various questionnaires in patients with a newly and previously diagnosed IPAH. Materials and methods . 73 patients with IPAH were included in the study, all patients filled out Qol questionnaires: universal (SF-36, EQ-5D-3L) and special for patients with pulmonary hypertension (CAMPHOR, PAH-SYMPACT, EmPHasis-10). Two groups were formed, comparable by age and gender: group 1-42 patients with newly diagnosed IPAH; group 2-31 patients with a previously diagnosed IPAH. Results . Significant differences in SF-36 were found in the scale of Mental Health (52 [40; 64] % in the first group and 60 [52; 80] % in the second, p=0,02) and Mental component summary (40,8 [34,3; 49,3] % and 49,1 [41,0; 55,9] %, respectively, p=0,03). According to the EQ-5D-3L results, differences were found in the Visual Analogue Scale (VAS) and EQ-5D Index: higher values were found in the second group (the median VAS score was 50 [40; 60] % in the first group and 60 [50; 70] % in the second, p=0,006, EQ-5D Index – 0,60 [0,30; 0,71] and 0,66 [0,57; 0,76], respectively, p=0,05). No significant differences were found in the results of CAMPHOR, PAH-SYMPACT, and EmPHasis-10 in two groups. Conclusions . Pathogenetic therapy promotes improvement of functional status of patients with IPAH. Low emotional status indicators in patients with a prevalent disease indicates the need to develop a system of psychological assistance for IPAH patients.
- 24 February 2026
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 46-53
Open AccessAnalysis of quality of life indicators using various questionnaires in patients with idiopathic pulmonary hypertension.
Idiopathic pulmonary hypertension (IPAH) is a rare severe disease with a poor prognosis. Assessing quality of life (QoL) using questionnaires can significantly complement clinical, laboratory and instrumental data. Aim . To assess QoL using various questionnaires in patients with a newly and previously diagnosed IPAH. Materials and methods . 73 patients with IPAH were included in the study, all patients filled out Qol questionnaires: universal (SF-36, EQ-5D-3L) and special for patients with pulmonary hypertension (CAMPHOR, PAH-SYMPACT, EmPHasis-10). Two groups were formed, comparable by age and gender: group 1-42 patients with newly diagnosed IPAH; group 2-31 patients with a previously diagnosed IPAH. Results . Significant differences in SF-36 were found in the scale of Mental Health (52 [40; 64] % in the first group and 60 [52; 80] % in the second, p=0,02) and Mental component summary (40,8 [34,3; 49,3] % and 49,1 [41,0; 55,9] %, respectively, p=0,03). According to the EQ-5D-3L results, differences were found in the Visual Analogue Scale (VAS) and EQ-5D Index: higher values were found in the second group (the median VAS score was 50 [40; 60] % in the first group and 60 [50; 70] % in the second, p=0,006, EQ-5D Index – 0,60 [0,30; 0,71] and 0,66 [0,57; 0,76], respectively, p=0,05). No significant differences were found in the results of CAMPHOR, PAH-SYMPACT, and EmPHasis-10 in two groups. Conclusions . Pathogenetic therapy promotes improvement of functional status of patients with IPAH. Low emotional status indicators in patients with a prevalent disease indicates the need to develop a system of psychological assistance for IPAH patients.
- Open Access
- 27 October 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (3) , 25-32
Clinical course and prognosis of patients with idiopathic pulmonary arterial hypertension after COVID-19
The coronavirus disease of 2019 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus (SARS-CoV-2). This virus has many factors in its pathogenesis that affect the function of the right ventricle and pulmonary hemodynamics, which can negatively influence the clinical course of IPAH. According to the results of our study, the fact of getting over COVID-19 in patients with IPAH leads to some changes in laboratory and instrumental parameters. But no significant effect of COVID-19 on risk modification during the year was detected. This result can be explained by a combination of pathophysiological features of the pulmonary hypertension and the protective effect of constantly taken PAH-specific and anticoagulant therapy.
- 27 October 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (3) , 25-32
Open AccessClinical course and prognosis of patients with idiopathic pulmonary arterial hypertension after COVID-19
The coronavirus disease of 2019 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus (SARS-CoV-2). This virus has many factors in its pathogenesis that affect the function of the right ventricle and pulmonary hemodynamics, which can negatively influence the clinical course of IPAH. According to the results of our study, the fact of getting over COVID-19 in patients with IPAH leads to some changes in laboratory and instrumental parameters. But no significant effect of COVID-19 on risk modification during the year was detected. This result can be explained by a combination of pathophysiological features of the pulmonary hypertension and the protective effect of constantly taken PAH-specific and anticoagulant therapy.